Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
9.80
+0.43 (4.59%)
At close: Feb 20, 2026, 4:00 PM EST
9.99
+0.19 (1.94%)
After-hours: Feb 20, 2026, 7:41 PM EST
Lipocine Employees
Lipocine had 16 employees as of December 31, 2024. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
$270,168
Profits / Employee
-$342,202
Market Cap
54.41M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 16 | -1 | -5.88% |
| Dec 31, 2023 | 17 | 0 | - |
| Dec 31, 2022 | 17 | 4 | 30.77% |
| Dec 31, 2021 | 13 | 2 | 18.18% |
| Dec 31, 2020 | 11 | -1 | -8.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| Metagenomi Therapeutics | 124 |
| PMV Pharmaceuticals | 47 |
| BeyondSpring | 40 |
| LeonaBio | 26 |
| MiNK Therapeutics | 23 |
| Nutriband | 13 |
| Spruce Biosciences | 9 |
LPCN News
- 4 days ago - Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PRNewsWire
- 4 weeks ago - Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 5 weeks ago - Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 2 months ago - Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PRNewsWire
- 3 months ago - Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 3 months ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PRNewsWire
- 3 months ago - Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PRNewsWire
- 5 months ago - Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) - PRNewsWire